An Open-label Pilot Study of Coenzyme Q10 in Steroid-Treated Duchenne Muscular Dystrophy

Muscular Dystrophy, Duchenne Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00033189
• Other study ID #: CNMC0301
• Status: Completed
• Phase: Phase 2
• First received: April 8, 2002
• Last updated: November 15, 2010
• Start date: September 2001
• Est. completion date: January 2005

Study information

• Verified date: November 2010
• Source: Cooperative International Neuromuscular Research Group
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study will help to determine the safety and efficacy of the nutritional supplement Coenzyme Q10 when added to steroids as a treatment for Duchenne muscular dystrophy (DMD). Boys with DMD who are enrolled in this study will should be on a stable dose of steroids for at least six months, and will remain on their usual dose throughout the study. They will complete two screening visits within a one-week period, and if enrolled will then have their strength tested monthly for three months before beginning therapy with Coenzyme Q10. Once Coenzyme Q10 therapy is started, participants will have their strength tested monthly for six months. Following the six month treatment period, participants will be given the option to remain on Coenzyme Q10 until the study is completed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: January 2005
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 5 Years to 11 Years

Eligibility

Subject Inclusion Criteria

1. Age: 5 - 11 years old

2. Ambulant

3. Diagnosis of DMD confirmed by at least one the following:

• Positive X-linked family history for typical Duchenne muscular dystrophy in older male relatives (onset by age 5 yr., wheelchair-bound by age 12 yr.) OR

• Dystrophin immunofluorescence and/or immunoblot showing complete dystrophin deficiency, and clinical picture consistent with typical Duchenne dystrophy OR

• Gene deletion test positive (missing one or more exons) in the central rod domain (exons 25-60) of dystrophin, where reading frame can be predicted as `out-of-frame', and clinical picture consistent with typical Duchenne dystrophy.

4. On Glucocorticosteroids: Children must be on a steady dose of prednisone or deflazacort, on any schedule (Daily, alternate days, 10 days on, 10 days off or twice a week), for the last 6 months before starting the clinical trial. Dose of steroid or schedule cannot be altered during the study.

5. Evidence of muscle weakness by MRC score or clinical functional evaluation

6. Ability to provide reproducible repeat QMT bicep score within 10% of first assessment score.

7. Ability to swallow tablets

Subject Exclusion Criteria

1. Failure to achieve one or more of the diagnostic inclusion criteria cited above.

2. Symptomatic DMD carrier

3. Previous (6 months or less) or current use of Coenzyme Q10 (for DMD or any other disease)

4. Use of carnitine, other amino acids, creatine, glutamine, or any herbal medicines within the last 3 months.

5. History of significant concomitant illness or significant impairment of renal or hepatic function.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Muscular Dystrophies
• Muscular Dystrophy, Duchenne

Intervention

Drug:
• Coenzyme Q10

Locations

Country	Name	City	State
United States	Washington University-St. Louis	St. Louis	Missouri
United States	Children's National Medical Center	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Cooperative International Neuromuscular Research Group

Country where clinical trial is conducted

United States,